Pharmaceutical Report Library l Report Store l Pharma Intelligence

Fovista

Fovista (pegpleranib; Ophthotech/Novartis) is a PEGylated aptamer targeting platelet-derived growth factor (PDGF). The drug is designed to be used in combination with a vascular endothelial growth factor (VEGF) inhibitor.

April 7, 2016

Find out more

Catch Up On CAR-T

$699.00

Sale!

With the approval of the first CAR-T therapies – Novartis’ Kymriah and Gilead/Kite’s Yescarta – what had been the promise of cutting-edge science is now reality.

November 24, 2017

Find out more

Datamonitor Healthcare HIV KOL Interview – US #1

$599.00

A US key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

January 25, 2019

Find out more

Disease Analysis: Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin’s lymphoma (NHL), which originates in the lymphatic system when B lymphocytes become enlarged and proliferate uncontrollably to form a tumor mass. DLBCL can arise de novo or as a progression or transformation from more indolent disease such as chronic lymphocytic leukemia (in which case it is also known as Richter’s transformation) or follicular lymphoma (FL).

October 12, 2022

Find out more

Remicade

Remicade (infliximab; Johnson & Johnson/Merck & Co/Mitsubishi Tanabe) is a chimeric, humanized monoclonal antibody targeting tumor necrosis factor (TNF)-alpha, with a long history of use in a number of immune-mediated inflammatory diseases, including Crohn’s disease, rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, Behçet’s syndrome, and ulcerative colitis.

August 2, 2018

Find out more

Market Spotlight: Insomnia

$1,318.00

This Market Spotlight report covers the insomnia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming events and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

September 29, 2022

Find out more

U.S. Markets for Pharmacologic and Device-Based Approaches to Pain Management

$4,750.00

More than 40% of people in the U.S. say they have experienced recent pain, with 8% suffering from chronic pain. Direct healthcare costs associated with the treatment of pain total nearly $300 billion annually.

April 4, 2016

Find out more

Specialty Endoscopic Surgery Devices Market

$4,750.00

The global market for specialty endoscopic surgery products totaled approximately $5.8bn in 2016, with the US comprising 48.2% of sales (or $2.8bn). Six major product segments are included in the specialty endoscopic surgery products market: endoscopes and equipment; suction/irrigation and fluid management systems, arthroscopic hand instruments, ENT/neurologic hand instruments, thoracoscopic hand instruments, and trocars.

August 23, 2017

Find out more

Remodulin

Remodulin (treprostinil; United Therapeutics/Antigen/Mochida) is a prostaglandin analog that functions as a prostaglandin I2 (PGI2) receptor agonist.

October 29, 2018

Find out more

Glyxambi

Glyxambi is a fixed-dose combination of sodium-glucose cotransporter-2 inhibitor Jardiance (empagliflozin; Boehringer Ingelheim/Eli Lilly) and dipeptidyl peptidase-IV inhibitor Tradjenta.

November 7, 2017

Find out more

UK Generics and Biosimilars

$2,995.00

Prescribing by international non-proprietary name, pharmacist incentives, and the high price differential between the brands and their generic alternatives are the key drivers of the generics market in the UK.

November 2, 2016

Find out more

Ganaxolone

Marinus Pharmaceuticals is developing ganaxolone, a first-in-class synthetic neurosteroid drug for the adjunctive treatment of status epilepticus and pediatric orphan indications.

May 23, 2017

Find out more

Company Analysis: Eli Lilly

$3,000.00

PharmaVitae explores Eli Lilly’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

January 25, 2021

Find out more

OncoVAX

OncoVAX (Vaccinogen) is a personalized cancer vaccine that uses the patient’s own cancer cells to prevent tumor progression after surgery.

December 11, 2017

Find out more

Nouriast

Nouriast (istradefylline; Kyowa Hakko Kirin) is the first, and so far, the only adenosine A2a receptor antagonist to be approved for the treatment of Parkinson’s disease. It acts to decrease overactivity of the indirect pathway of the motor circuit that is present in Parkinson’s disease patients with low dopamine levels.

June 21, 2018

Find out more

Beraprost 314d

Beraprost (United Therapeutics/Astellas/Kaken Pharmaceutical Co) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor…

June 19, 2015

Find out more

Adempas

Adempas (riociguat; Bayer/Merck & Co) is a first-in-class drug that activates soluble guanylyl cyclase (sGC), a key enzyme in nitric oxide-mediated vasodilation of vascular smooth muscle cells.

October 29, 2018

Find out more

Rebinyn

Rebinyn is a glycoPEGylated rebombinant factor IX (rfIX) therapy developed by Novo Nordisk for the treatment of hemophilia B.

May 20, 2018

Find out more

Firmagon

Firmagon (degarelix; Ferring/Astellas) is a gonadotropin-releasing hormone (GnRH) receptor antagonist that directly binds to GnRH receptors in the anterior pituitary gland, rapidly reducing the circulating gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and leading to the rapid suppression of testosterone in men.

January 18, 2018

Find out more

Daromun

Daromun (Philogen) is a combination of Darleukin, a human vascular targeting monoclonal antibody (L19) fused to interleukin-2 (IL-2), and Fibromun, the L19 antibody linked to tumor necrosis factor (TNF). Both IL-2 and TNF are cytokines, key signaling molecules that are involved with the coordination of immunity.

May 23, 2018

Find out more

Diabetes Management: Insulin Pumps Market (2019)

$4,750.00

This report provides an overview of diabetes, automated insulin pump systems, and a comprehensive market and competitive analysis.

September 30, 2019

Find out more

Banzel

Eisai’s Banzel is an oral sodium channel modulator which is structurally different from currently approved anticonvulsants on account of its triazole derivative structure. The drug’s sole approved indication is the adjunctive treatment of seizures…

May 23, 2017

Find out more

United States, Cardiovascular Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

$1,995.00

This report presents the prevalence and number of hospital discharges in the UnitedStates (U.S.) as well as the surgical procedure volumes for selected cardiovascular/thoracic diseases/disorders.

January 1, 2013

Find out more

Multiple Sclerosis (MS) KOL Interview – UK, London

$599.00

In this interview, a UK-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

March 2, 2020

Find out more

Epidiolex

GW Pharmaceuticals is developing Epidiolex, a first-in-class cannabinoid drug for the treatment of

childhood seizures.

May 23, 2017

Find out more

Disease Analysis: Epilepsy

Epilepsy is characterized by recurrent, unprovoked seizures, and is one of the most common chronic neurological disorders globally. A seizure is a transient manifestation of signs and/or symptoms, including a disturbance of consciousness, emotion, behavior, or motor function, which occurs because of abnormal excessive or synchronous neuronal activity in the brain.

May 6, 2022

Find out more

Stivarga

Stivarga (regorafenib; Bayer/Amgen) is an orally available small molecule inhibitor that is currently in development for the treatment of hepatocellular carcinoma (HCC).

September 9, 2019

Find out more

Palbociclib for Breast Cancer

$89.00

Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer

February 1, 2014

Find out more

Market Spotlight: Huntington’s Disease

$1,318.00

This Market Spotlight report covers the Huntington’s Disease market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

October 6, 2022

Find out more

Abraxane

Abraxane (nab-paclitaxel; Bristol-Myers Squibb) is a novel albumin-bound formulation of paclitaxel. Paclitaxel is an insoluble taxane classified as an anti-microtubule agent; it stops the growth of tumors by inhibiting mitosis during metaphase.

February 26, 2020

Find out more

Report library

Fovista

Catch Up On CAR-T

Datamonitor Healthcare HIV KOL Interview – US #1

Disease Analysis: Diffuse Large B-Cell Lymphoma (DLBCL)

Remicade

Market Spotlight: Insomnia

U.S. Markets for Pharmacologic and Device-Based Approaches to Pain Management

Specialty Endoscopic Surgery Devices Market

Remodulin

Glyxambi

UK Generics and Biosimilars

Ganaxolone

Company Analysis: Eli Lilly

OncoVAX

Nouriast

Beraprost 314d

Adempas

Rebinyn

Firmagon

Daromun

Diabetes Management: Insulin Pumps Market (2019)

Banzel

United States, Cardiovascular Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

Multiple Sclerosis (MS) KOL Interview – UK, London

Epidiolex

Disease Analysis: Epilepsy

Stivarga

Palbociclib for Breast Cancer

Market Spotlight: Huntington’s Disease

Abraxane